معرفی
Caroline Arber Barth is an Associate Professor at the University of Lausanne (UNIL), affiliated with the Faculty of Biology and Medicine and the UNIL-CHUV Department of Oncology. She specializes in hematology and immuno-oncology, with a focus on hematopoietic cell transplantation and immunotherapy using genetically modified cells.
Her research spans basic, translational, and clinical domains, aiming to improve cancer immunotherapies through adoptive T cell transfer and neoantigen identification. She has pioneered approaches to reduce post-transplant infections and enhance immune reconstitution. Her work targets long-term tumor control while minimizing toxicity in patients.
The trends in her publications reflect a strong focus on cellular therapies, particularly CAR-T and TCR-modified T cells, for treating hematological malignancies such as leukemia, lymphoma, and myeloma. Her research integrates molecular engineering, tumor immunology, and clinical applications, emphasizing personalized treatment strategies.
Awarded international recognition, her scientific honors include:
- Dean's Recognition, Stanford University (2002)
- L'Oréal UNESCO Award for Women in Science (2010)
- Award from the American Society of Bone Marrow Transplantation (2012)
- Award from the American Society of Hematology (2013)
She has secured major research funding from the NIH, SNSF, Oncosuisse, the Leukemia and Lymphoma Society, and the Cancer Prevention and Research Institute of Texas. She has supervised multiple undergraduate and doctoral students and is actively involved in teaching at both Swiss and U.S. institutions. Her laboratory, based at the Center for Cellular and Gene Therapy (CAGT) during her time in Houston and now at UNIL-CHUV, focuses on developing next-generation cell therapies for cancer.
